Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease,
Год журнала:
2024,
Номер
1871(3), С. 167637 - 167637
Опубликована: Дек. 23, 2024
With
few
viable
treatment
options,
glioblastoma
(GBM)
is
still
one
of
the
most
aggressive
and
deadly
types
brain
cancer.
Recent
developments
in
lipidomics
have
demonstrated
potential
lipid
metabolism
as
a
therapeutic
target
GBM.
The
thorough
examination
lipids
biological
systems,
or
lipidomics,
essential
to
comprehending
changed
profiles
found
GBM,
which
are
linked
tumor's
ability
grow,
survive,
resist
treatment.
use
drug
delivery
discovery
examined
this
study,
focusing
on
how
it
may
be
used
find
new
biomarkers,
create
multi-target
directed
ligands,
improve
systems.
We
also
cover
FDA-approved
medications,
clinical
trials
that
lipid-targeted
medicines,
integration
with
other
omics
technologies.
This
study
emphasizes
possible
tool
developing
more
effective
methods
for
GBM
by
exploring
various
lipid-centric
techniques.
Advanced Functional Materials,
Год журнала:
2024,
Номер
unknown
Опубликована: Ноя. 5, 2024
Abstract
Glioblastoma
(GBM)
is
a
highly
malignant
intracranial
tumor
with
limited
treatment
options.
Bispecific
T‐cell
engagers
(BiTEs)
are
being
explored
for
GBM
treatment,
but
their
success
hindered
by
inadequate
T
cell
infiltration
and
activation
due
to
the
acidic
immunosuppressive
microenvironment.
Photothermal
immunotherapy
lyses
tumors
activates
immune
responses,
complementing
BiTEs.
This
study
innovatively
employs
donor
engineering
strategy
develop
hemicyanine
dyes
(Hcys)
that
emit
from
near‐infrared
(NIR)
I
NIR
II.
The
Hcy
excellent
properties
encapsulated
in
an
amphiphilic
micelle,
forming
nano
assembly
lactate
oxidase
(PLH1100).
PLH1100
exhibits
spectral
absorption
at
980
nm,
photothermal
conversion
efficiency
of
58.7%,
capability
NIR‐II
imaging.
Besides
ablation,
regulates
lactic
acid
metabolism
immunogenic
death,
improving
microenvironment
promoting
activation.
Further
studies
demonstrate
effectively
kills
human
murine
cells,
inhibits
orthotopic
U87
growth
BALB/c‐nu
mice,
enhances
efficacy
Fn14‐targeted
BiTE
GL261
C57BL/6
achieving
synergistic
“1+1>2”
therapeutic
effect.
Collectively,
this
work
opens
new
pathway
using
Hcy‐based
molecules
combined
drugs
therapy,
significant
clinical
potential.
Current Issues in Molecular Biology,
Год журнала:
2024,
Номер
46(12), С. 14324 - 14350
Опубликована: Дек. 19, 2024
Glioblastoma
multiforme
(GBM)
is
one
of
the
most
aggressive
and
difficult-to-treat
brain
tumors,
with
a
poor
prognosis
due
to
its
high
resistance
conventional
therapies.
Current
treatment
options,
including
surgical
resection,
radiotherapy,
chemotherapy,
have
limited
effectiveness
in
improving
long-term
survival.
Despite
emergence
new
therapies,
monotherapy
approaches
not
shown
significant
improvements,
highlighting
need
for
innovative
therapeutic
strategies.
Combination
therapies
appear
be
promising
solution,
as
they
target
multiple
molecular
pathways
involved
GBM
progression.
One
area
growing
interest
incorporation
phytotherapy
micotherapy
complementary
treatments,
which
offer
potential
benefits
their
anti-tumor,
anti-inflammatory,
immunomodulatory
properties.
This
review
examines
current
challenges
treatment,
discusses
combination
highlights
role
integrative
options
management.
Research Square (Research Square),
Год журнала:
2024,
Номер
unknown
Опубликована: Окт. 25, 2024
Abstract
Glioblastoma,
IDH-wildtype
(GBM,
WHO
grade
4)
is
the
most
common
and
lethal
type
of
brain
cancer
that
hard
to
cure.
Among
3
subtypes
GBM,
mesenchymal
GBM
characterized
by
therapeutic
resistance
poor
outcomes.
Here,
we
found
both
STAT3
NF-κB
pathways
are
abnormally
activated
in
patients
with
higher
expression
had
a
prognosis
TCGA
database.
Using
inhibitor,
Stattic,
suppress
signaling
cells.
However,
it
was
observed
Stattic
alone
leads
compensatory
activation
signaling.
Therefore,
hypothesized
combined
inhibition
may
has
better
anti-mesenchymal
effect
than
single
inhibition.
ACT001,
novel
synergistic
anti-GBM
effect,
effectively
inhibiting
proliferation,
invasion,
migration
promoting
apoptosis.
RNA-seq
analysis
showed
resulted
suppression
downstream
gene
PLK4
compared
either
pathway
alone.
Overexpression
enhance
cell
invasion
migration,
while
reducing
Taken
together,
these
findings
suggest
targeting
pathways,
acting
on
PLK4,
suppresses
as
well
promotes
apoptosis
subtype
cells,
offering
strategy
for
GBM.
Kinases and Phosphatases,
Год журнала:
2024,
Номер
2(4), С. 391 - 412
Опубликована: Дек. 22, 2024
Glioblastoma
stem
cells
(GSCs)
are
key
drivers
of
relapse,
metastasis,
and
therapy
resistance
in
glioblastoma
due
to
their
adaptability
diversity,
which
make
them
challenging
target
effectively.
This
study
explores
the
O-glycosylation
differentiating
two
GSC
subtypes,
CD133
CD44.
We
utilized
TCGA
dataset
GBM
presented
reproducible
bioinformatics
analysis
for
our
results.
Our
profiling
showed
enriched
signatures
CD44-expressing
over
CD133,
with
Cosmc,
chaperone
core
mucin-type
O-glycosylation,
significantly
upregulated
CD44-positive
group.
Moreover,
Cosmc
was
associated
shorter
progression-free
intervals,
suggesting
its
potential
as
an
indicator
aggressive
disease.
High
expression
also
immune-related
pathways,
including
inflammatory
response
antigen
presentation,
presence
myeloid
cells,
T
NK
cells.
Additionally,
elevated
correlated
extracellular
matrix
(ECM)
pathways
stromal
cell
populations,
such
perivascular
fibroblasts.
These
findings
position
specially,
a
promising
biomarker
distinguishing
subclones,
relevance
immune
modulation,
ECM
dynamics,
identifying
it
novel
therapies.
Life,
Год журнала:
2024,
Номер
14(10), С. 1312 - 1312
Опубликована: Окт. 16, 2024
Using
microRNAs
(miRNAs)
as
potential
circulating
biomarkers
in
diagnosing
and
treating
glioblastoma
(GBM)
has
garnered
a
lot
of
scientific
clinical
impetus
the
past
decade.
As
an
aggressive
primary
brain
tumor,
GBM
poses
challenges
early
detection
effective
treatment
with
significant
current
diagnostic
constraints
limited
therapeutic
strategies.
MiRNA
dysregulation
is
present
GBM.
The
intricate
involvement
miRNAs
altering
cell
proliferation,
invasion,
immune
escape
makes
them
prospective
candidates
for
identifying
monitoring
diagnosis
response
to
treatment.
These
could
play
dual
role,
acting
both
markers
targets
therapy.
By
modulating
activity
various
oncogenic
tumor-suppressive
proteins,
create
opportunities
precision
medicine
targeted
therapies
This
review
centers
on
critical
role
function
miRNA
It
highlights
their
significance
providing
insights
into
disease
progression,
aiding
diagnosis,
use
novel
interventions.
Ultimately,
study
would
contribute
improving
patient
outcomes
challenging
landscape
management.
International Journal of Advanced Pharmaceutical Sciences and Research,
Год журнала:
2024,
Номер
4(6), С. 49 - 57
Опубликована: Окт. 28, 2024
This
study
presents
a
retrospective
analysis
of
glioblastoma
cases
admitted
to
Tishreen
University
Hospital
in
Lattakia,
Syria,
between
February
and
August
2024.
The
examines
the
several
potential
risk
factors
including
age,
sex,
genetic
predispositions,
lifestyle
such
as
smoking
alcohol
consumption.
It
also
explores
most
commonly
encountered
tumor
grade
presence
various
neurological
symptoms,
well
treatment
outcomes.
A
total
30
were
enrolled
this
study,
63%
which
males,
highest
age
incidence
was
40
50
years.
Only
6%
had
family
history
glioblastoma,
66%
patients
smokers.
Memory
disorders,
visual
impairments,
headaches
common
with
100%
reporting
nausea
vomiting.
Glioblastoma
diagnosis
primarily
established
through
MRI
contrast
(76%),
predominant
modality
surgery
combined
radiotherapy
chemotherapy
(80%).
Post-treatment
relapse
occurred
26%
patients,
median
remission
period
four
months.
These
findings
provide
important
insights
into
clinical
characteristics
outcomes
region.
Brain Sciences,
Год журнала:
2024,
Номер
14(12), С. 1164 - 1164
Опубликована: Ноя. 21, 2024
This
paper
presents
the
basis
for
LoGlo
PDT,
a
new
treatment
glioblastoma.
Glioblastoma
is
currently
treated
with
maximal
safe
resection,
temozolomide,
and
ionizing
irradiation.
Mortality
in
2024
remains
over
80%
within
several
years
from
diagnosis.
Oral
5-aminolevulinic
acid
(5-ALA)
an
FDA/EMA
approved
drug
that
selectively
taken
up
by
malignant
cells,
including
In
photodynamic
of
glioblastoma,
intense
intraoperative
light
causes
glioblastoma
tissue
has
5-ALA
to
generate
cytotoxic
reactive
oxygen
species.
The
requirement
flux
restricted
single
one-hour
session.
We
analyze
here
published
data
showing
external
light,
illuminating
entire
intact
scalp,
can
attain
low
μW/cm2
cm
into
brain
would
be
sufficient
mediate
if
are
delivered
continuously
24
h.
At
core
PDT
regimen
dataset
that,
given
fluence,
as
duration
delivery
goes
down,
intensity
(flux)
must
go
achieve
same
cell
cytotoxicity
weaker
(lower
flux)
longer
time.
Thus,
repetitive,
noninvasive
using
source
may
possible.
cellular
physiology
show
three
non-oncology
drugs,
ciprofloxacin,
deferiprone,
telmisartan,
repurposed
increase
energy
capture
after
5-ALA,
thereby
increasing
treatment’s
cytotoxicity.
approach
uses
both
augmentation
prolonged
ultra-low
transcranial
